Wave Life Sciences Reports First Quarter 2020 Financial Results and Provides Business Update
11 mai 2020 07h30 HE
|
Wave Life Sciences USA, Inc.
Data from both PRECISION-HD clinical trials expected in 2H 2020 Advancing clinical neurology pipeline − SNP3 and C9orf72 programs on track to initiate clinical development in 2H 2020 First...
Wave Life Sciences to Webcast Conference Call of First Quarter 2020 Financial Results on May 11, 2020
29 avr. 2020 16h05 HE
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., April 29, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
uniQure Announces First Quarter 2020 Financial Results and Highlights Recent Company Progress
29 avr. 2020 07h00 HE
|
uniQure Inc.
~ Completed Target Patient Dosing in Phase III HOPE-B Trial of Etranacogene Dezaparvovec in Hemophilia B ~ ~ Announced 22 Presentations at Upcoming ASGCT Virtual Annual Meeting ~ LEXINGTON, Mass....
AskBio Acquires BrainVectis to Expand its Clinical Pipeline for Neurodegenerative Diseases
22 avr. 2020 08h05 HE
|
Asklepios BioPharmaceutical, Inc.
RESEARCH TRIANGLE PARK, N.C. and PARIS, April 22, 2020 (GLOBE NEWSWIRE) -- Asklepios BioPharmaceutical, Inc. (AskBio), a leading, clinical-stage adeno-associated virus (AAV) gene therapy company,...
uniQure Announces Achievement of Target Patient Dosing in HOPE-B Pivotal Trial of AMT-061 (Etranacogene Dezaparvovec) in Hemophilia B
26 mars 2020 07h00 HE
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, March 26, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet...
Vaccinex Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
09 mars 2020 07h46 HE
|
Vaccinex, Inc.
On-track to report topline data from CLASSICAL-Lung and SIGNAL clinical trials this year Announces expansion of pepinemab development program into Alzheimer’s disease Completes private placement of...
uniQure Announces 2019 Financial Results and Highlights Recent Company Progress
02 mars 2020 16h05 HE
|
uniQure Inc.
~ Patient Dosing Nearly Completed in Phase III HOPE-B Trial of Etranacogene Dezaparvovecin Hemophilia B ~ ~ First Patient Procedure in Phase I/II Clinical Trial of AMT-130 in Huntington’s Disease...
uniQure Presents Multiple New Preclinical Data on AMT-130 at the CHDI’s 15th Annual Huntington’s Disease Therapeutics Conference
27 févr. 2020 07h00 HE
|
uniQure Inc.
~ Up to Two Years of Follow-up in Large Transgenic Huntington’s Disease Model Demonstrates Stable mHTT Protein Lowering ~ ~ Novel Preclinical Data Demonstrates Successful Lowering of Pathogenic Exon...
uniQure Announces Publication of Preclinical Data for AMT-130 in Huntington’s Disease Supporting Non-Selective HTT-Lowering Approach
19 déc. 2019 07h00 HE
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Dec. 19, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
uniQure to Participate in Multiple Upcoming Industry Conferences in September
30 août 2019 07h00 HE
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Aug. 30, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...